At the end of the latest market close, Ensysce Biosciences Inc. (ENSC) was valued at $2.45. In that particular session, Stock kicked-off at the price of $2.48 while reaching the peak value of $2.52 and lowest value recorded on the day was $2.41. The stock current value is $2.74.Recently in News on September 27, 2021, Ensysce Biosciences Announces $15 Million Convertible Note Financing. Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, announced today that it has entered into a securities purchase agreement with institutional investors (“Investors”) in the form of senior secured convertible notes (the “Notes”) and warrants exercisable for Ensysce common stock (the “Warrants”) in a private placement for an aggregate investment of $15 million. An initial funding by the Investors occurred on September 24, 2021, for $5 million prior to fees and offering expenses. You can read further details here
Ensysce Biosciences Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $23.99 on 02/01/21, with the lowest value was $2.23 for the same time period, recorded on 10/06/21.
Ensysce Biosciences Inc. (ENSC) full year performance was -76.49%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Ensysce Biosciences Inc. shares are logging -88.58% during the 52-week period from high price, and 22.87% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.23 and $23.99.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 702932 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Ensysce Biosciences Inc. (ENSC) recorded performance in the market was -80.30%, having the revenues showcasing -76.33% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 60.22M.
Specialists analysis on Ensysce Biosciences Inc. (ENSC)
During the last month, 0 analysts gave the Ensysce Biosciences Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 7.45, with a change in the price was noted -10.67. In a similar fashion, Ensysce Biosciences Inc. posted a movement of -79.07% for the period of last 100 days, recording 1,237,705 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ENSC is recording 0.26 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.26.
Trends and Technical analysis: Ensysce Biosciences Inc. (ENSC)
Raw Stochastic average of Ensysce Biosciences Inc. in the period of last 50 days is set at 16.38%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 17.75%. In the last 20 days, the company’s Stochastic %K was 10.31% and its Stochastic %D was recorded 6.90%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -80.30%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -81.48%, alongside a downfall of -76.49% for the period of the last 12 months. The shares -2.78% in the 7-day charts and went up by -22.22% in the period of the last 30 days. Common stock shares were lifted by -76.33% during last recorded quarter.